AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis.
about
Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumorsCEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis.CSF2 Overexpression Is Associated with STAT5 Phosphorylation and Poor Prognosis in Patients with Urothelial Carcinoma.Transcriptomic reappraisal identifies MGLL overexpression as an unfavorable prognosticator in primary gastrointestinal stromal tumors.DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study.MCM10 overexpression implicates adverse prognosis in urothelial carcinoma.PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival.Sulfatase-1 overexpression indicates poor prognosis in urothelial carcinoma of the urinary bladder and upper tractGastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis.Metabolic Stress-Induced Phosphorylation of KAP1 Ser473 Blocks Mitochondrial Fusion in Breast Cancer Cells.High frequency of the SDK1:AMACR fusion transcript in Chinese prostate cancer.Ki67 Proliferation Index as a Histopathological Predictive and Prognostic Parameter of Oral Mucosal Melanoma in Patients without Distant Metastases.AMACR overexpression acts as a negative prognostic factor in oral squamous cell carcinoma.
P2860
Q28602517-C475CFF6-337E-4AB2-9B5A-E1B1F015F28EQ35755517-DCC738A9-4737-4CD5-AE62-2722E7A59585Q35989342-98CD8B6C-D82D-48BA-AAC9-AADB28C49AD6Q37580351-9F614C26-69B0-4676-B1FF-FF52A94200E9Q37694728-1197F2E4-67AD-4685-985B-6A686DED80E6Q37718437-1938E4C3-8100-4AB2-9E05-E128CFA733D3Q37746218-E8BC2573-2DB9-4504-BD72-501183049690Q38774630-F8A10AEC-28BF-4C0C-A9E2-4B11F24D1ED8Q39068344-7934048D-36E6-4843-B84F-19619D32E0EDQ42320736-D3A9D438-5887-4FC3-A225-488606657E67Q43156871-3F4B6AFE-493B-4EF7-A978-34B4E2395D44Q47156241-B552DE0C-F5F8-403F-AE72-DEE7CE7A81CFQ55400470-E32F759B-B1C2-45D9-ABEE-789F7DE5140A
P2860
AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
AMACR amplification and overex ...... indicating adverse prognosis.
@ast
AMACR amplification and overex ...... indicating adverse prognosis.
@en
AMACR amplification and overex ...... indicating adverse prognosis.
@nl
type
label
AMACR amplification and overex ...... indicating adverse prognosis.
@ast
AMACR amplification and overex ...... indicating adverse prognosis.
@en
AMACR amplification and overex ...... indicating adverse prognosis.
@nl
prefLabel
AMACR amplification and overex ...... indicating adverse prognosis.
@ast
AMACR amplification and overex ...... indicating adverse prognosis.
@en
AMACR amplification and overex ...... indicating adverse prognosis.
@nl
P2093
P2860
P356
P1433
P1476
AMACR amplification and overex ...... indicating adverse prognosis.
@en
P2093
Chien-Feng Li
Ching-Yih Lin
Fong-Fu Chou
Fu-Ming Fang
Hsuan-Ying Huang
Hui-Chun Tai
Li-Tzong Chen
Shau-Hsuan Li
Shih-Chen Yu
P2860
P304
11588-11603
P356
10.18632/ONCOTARGET.2597
P407
P577
2014-11-01T00:00:00Z